Highline Wealth Partners LLC Sells 58 Shares of Danaher Co. (NYSE:DHR)

Highline Wealth Partners LLC cut its position in Danaher Co. (NYSE:DHR) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,326 shares of the conglomerate’s stock after selling 58 shares during the quarter. Highline Wealth Partners LLC’s holdings in Danaher were worth $1,682,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the 3rd quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher during the third quarter worth about $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher in the third quarter worth about $50,000. Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at approximately $55,000. Finally, Modus Advisors LLC bought a new position in Danaher in the 4th quarter worth approximately $56,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 0.9 %

Shares of DHR traded down $2.03 on Friday, hitting $236.06. 1,355,819 shares of the stock traded hands, compared to its average volume of 2,598,840. The firm has a market capitalization of $170.50 billion, a P/E ratio of 45.05, a P/E/G ratio of 4.33 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The stock’s 50 day moving average is $235.93 and its two-hundred day moving average is $253.88.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company posted $2.02 earnings per share. The firm’s revenue was up 3.1% compared to the same quarter last year. As a group, sell-side analysts predict that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DHR shares. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Evercore ISI upped their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Scotiabank initiated coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Finally, Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.